Status: Open
Specialty: Radiotherapy
Date Opened: 09/02/2023
Planned Close Date: 31/03/2024
Sponsor: Commercial
Principal Investigator: Mr Isaac Phang
Study Title: Pivotal, randomised, open-label study of tumor treating fields (TTFields, 200kHz) concomitant with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma
This study describes a randomised open-label trial using a device called Optune® concomitant with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma multiforme (brain cancer). Optune® is a commercial portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200 kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division and it is intended to be used continuously for at least 18 hours per day on a monthly average.
Optune® has been approved for the treatment of recurrent and newly diagnosed glioblastoma (GBM) by the Food and Drug Administration (FDA) in the United States and has obtained a CE mark in Europe for the same indications.
Given the recent accumulated pre-clinical and clinical evidence, all strongly suggest that there is an advantage in starting TTFields treatment for newly diagnosed GBM patients as early as possible. Unlike in the currently approved indication, this study will start TTFields treatment concomitantly with RT and TMZ chemotherapy. Pre-clinical data have demonstrated additional benefits to start TTFields concurrently with RT and TMZ on tumor cells. Furthermore, recent pilot clinical studies also suggest that concomitant TTFields application with RT and TMZ chemotherapy is safe and feasible.
950 people worldwide with newly diagnosed glioblastoma aged 18 and older, who are planned to have chemoradiotherapy and adjutant chemotherapy (Stupp protocol) after surgery, will participate in this study. It is proposed that at least 35 of these people will be in England. The study is expected to last for 72 months.
1. Histologically confirmed diagnosis of GBM according to WHO classification criteria.
2. Age ≥ 18 years
3. Recovered from maximal debulking surgery, if applicable (gross total resection, partial resection and biopsy-only patients are all acceptable)
4. Planned treatment with RT/TMZ followed by TTFields and maintenance TMZ (150-200 mg/m2 daily x 5 d, q28 days)
5. Karnofsky performance status ≥ 70
6. Life expectancy ≥ least 3 months
7. Participants of childbearing age must use highly effective contraception. An effective method of birth control is defined as one that results in a failure rate of less than 1% per year when used consistently and correctly. The Investigator must approve the selected method, and may consult with a gynaecologist as needed.
8. All patients must understand and voluntarily sign an informed consent document prior to any study related assessments/ procedures being conducted.
9. Stable or decreasing dose of corticosteroids for the last 7 days prior to randomization, if applicable.
10. Concomitant RT with TMZ treatment planned to start no later than 8 weeks from surgery.
11. Women of childbearing potential must have a negative β-HCG pregnancy test documented within 14 days prior to registration.
12. Is able to have MRI with contrast of the brain.
1. Progressive disease (per investigator’s assessment)
2. Infratentorial or leptomeningeal disease
3. Participation in another clinical treatment study during the pre-treatment and/or the treatment phase of the study
4. Pregnancy or breast-feeding.
5. Significant co-morbidities at baseline which would preclude maintenance RT or TMZ treatment, as determined by the investigator:
a. Thrombocytopenia (platelet count < 100 x 103/μL)
b. Neutropenia (absolute neutrophil count < 1.5 x 103/μL)
c. CTC grade 4 non-haematological Toxicity (except for alopecia, nausea, vomiting)
d. Significant liver function impairment - AST or ALT > 3 times the upper limit of normal
e. Total bilirubin > 1.5 x upper limit of normal
f. Significant renal impairment (serum creatinine > 1.7 mg/dL, or > 150 µmol/l)
g. History of any psychiatric condition that might impair patient’s ability to understand or comply with the requirements of the study or to provide consent
6. Implanted pacemaker, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.
7. Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)
8. History of hypersensitivity reaction to TMZ or a history of hypersensitivity to DTIC.
9. Any other cytotoxic or biologic anti-tumor therapy received prior to enrollment will be considered exclusion.
10. Admitted to an institution by administrative or court order.
11. Known allergies to medical adhesives or hydrogel
12. A skull defect (such as, missing bone with no replacement)
13. Prior radiation treatment to the brain for the treatment of GBM
14. Any serious surgical/post-operative condition that may risk the patient according to the investigator
15. Standard TTFields exclusion criteria include
a. Active implanted medical devices
b. Bullet fragments
c. Skull defects
Radiotherapy Clinical Trials Radiographer: Jacqueline Hudson (x3317) Jacqueline.Hudson@LTHTR.nhs.uk
Link to EDGE